Blood Advances Study: Preeclampsia Risk in Sickle Cell Disease
American Society of Hematology shared an inviting post on LinkedIn:
“In pregnant women with sickle cell disease, the risk of developing early-onset preeclampsia can be determined by measuring levels of a protein associated with placental function and development, according to research published today in Blood Advances.
Placental growth factor (PlGF) is a protein produced by the placenta that supports the development of blood vessels. Measuring PlGF levels can help assess the risk of preeclampsia, a potentially deadly pregnancy complication that usually arises after 20 weeks and is characterized by high blood pressure and protein in the urine.
Women with sickle cell disease are more than 2.4 times likely to develop preeclampsia during pregnancy when compared to women without this condition. This complication can inhibit growth of the fetus, result in premature birth, and is associated with stroke and potential organ damage in the mother.
New findings provide insight that may help clinicians to anticipate and mitigate adverse pregnancy outcomes.
Read more about this new study.”

Stay up-to-date with the latest advancements in hematology through Hemostasis Today.
-
Mar 17, 2026, 18:11Ossama Mansour: Landmark MENA Guidelines for Acute Ischemic Stroke Management
-
Mar 17, 2026, 17:48Andrea Van Beek: Improving DOAC Adherence Saves Lives
-
Mar 17, 2026, 17:43Soumen Bhattacharyya: Microangiopathic Hemolytic Anemia Is Often a Hematologic Clue to Underlying Malignancy
-
Mar 17, 2026, 17:37Peter Bou Dib: New Insights on Factor VIII and the Musculoskeletal System
-
Mar 17, 2026, 17:31Armghan Ans: The 2026 Stroke Guidelines Are Excellent, Now the Hard Part
-
Mar 17, 2026, 17:26Danny Hsu: Navigating a Rebalanced Hemostatic State in Decompensated Cirrhosis
-
Mar 17, 2026, 17:21Matías J Alet on Acute Ischemic Stroke With Low NIHSS at NeuroQuality
-
Mar 17, 2026, 17:16S1PR4 Controls Platelet Fibrinogen Binding and Thrombus Formation – JTH
-
Mar 17, 2026, 15:55Mostafa Faisal Mohammed Saleh: Evidence-Based Recommendations for Hodgkin Lymphoma Management in LMICs